1003 results about "RNA - Ribonucleic acid" patented technology

The embodiments of the present disclosure relate to decreasing the bioavailability of one or more target biomolecules by providing a composition that comprises a recombinant plasmid with one or more sequences of micro interfering ribonucleic acid (miRNA). When the recombinant plasmid interacts with a target cell, it causes the target cell to upregulate production of the miRNA, which then decreases the bioavailability of the target biomolecule. In some embodiments of the present disclosure, the target biomolecule is a cytokine or other mediator molecule of an inflammatory response.

The embodiments of the present disclosure relate to one or more compositions or methods that upregulate the production of one or more sequences of micro-interfering ribonucleic acid (miRNA). The sequences of miRNA may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule, such as JAK. The miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA. Decreasing the bioavailability of the target biomolecule within a subject that is administered the one or more compositions may address the afflictions experienced by the subject due to expression of the target biomolecule.

The embodiments of the present disclosure relate to one or more compositions or methods that upregulate the production of one or more sequences of micro interfering ribonucleic acid (miRNA). The sequences of miRNA may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule, such as ETS2. The miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA. Decreasing the bioavailability of the target biomolecule within a subject that is administered the one or more compositions may address the afflictions experienced by the subject due to overexpression of the target biomolecule.

Provided herein are gene editing pairs comprising an engineered protein, e.g, an engineered CRISPR protein and a guide ribonucleic acid (gRNA) that may provide improved gene editing relative to reference, i.e., wild type sequences. In some embodiments, the engineered protein of the gene editing pair comprises a RuvC cleavage domain with one or more amino acid modifications relative to a reference CRISPR protein RuvC sequence. In some embodiments, a guide ribonucleic acid (gRNA) of the gene editing pair comprises at least one modification in a scaffold stem loop relative to a reference scaffold stem loop sequence.

The invention discloses an RNA (Ribonucleic Acid) in-vitro cyclization and rolling circle translation method based on an I-type intron and an application of the RNA in-vitro cyclization and rolling circle translation method. According to the invention, a ribonucleic acid construct is obtained by splitting a specific non-complementary region of the I-type intron, and the preparation of'scarless' (traceless) circular RNA is realized through a ribozyme self-splicing principle and can be popularized to other I-type intron. By optimizing a splitting structure, high-efficiency cyclization can be realized without additionally adding GTP for catalysis under the condition of no homologous arm. Meanwhile, the original part of the ribonucleic acid construct is optimized, so that the cyclization efficiency is further improved. Particularly, a rolling circle translation (RCT) technical platform based on the CITE sequence is established, and the expression quantity of the protein or the polypeptide is greatly improved. Through verification, the cyclization and rolling circle translation method provided by the invention shows potential in vaccine and CAR treatment, and is expected to be used for clinical treatment of various diseases.

The invention relates to the technical field of virus detection, and discloses a method for detecting infectious salmon anemia virus in salmon based on RAA-CRISPRCas12a and application, and the method comprises the following steps: dispersing a Cas12a protein solution, a guide RNA solution, an ssDNA reporter probe solution, a ribonuclease inhibitor, nuclease-free water and an RAA reactant in a buffer solution, incubating, and detecting the infectious salmon anemia virus in salmon based on RAA-CRISPRCas12a. Carrying out fluorescence intensity detection; the amino acid sequence of the Cas12a protein is as shown in SEQ ID NO. 6. The novel Cas12a protease with better cutting activity is used in the method, and can be successfully applied to detection of the infectious salmon anemia virus in salmons.

The invention relates to the technical field of virus detection, and discloses a method for detecting salmon alphavirus in salmon based on RAA-CRISPRCas12a and application, the method comprises the following steps: dispersing a Cas12 protein solution, a guide RNA solution, an ssDNA reporter probe solution, a ribonuclease inhibitor, nuclease-free water and an RAA reactant in a buffer solution, incubating, and carrying out fluorescence intensity detection; the amino acid sequence of the Cas12 protein is as shown in SEQ ID NO. 5. The novel Cas12a protease with better cutting activity is used in the method, and can be successfully applied to detection of salmon alphavirus in salmons.

Disclosed are compositions comprising a nucleic acid molecule. The nucleic acid molecule may encode an exonic sequence or portion thereof of a target ribonucleic acid (RNA) sequence. The nucleic acid molecule may further encode one or more stabilization domains. The one or more stabilization domains may be configured to reduce a cellular nuclease activity compared to a nucleic acid molecule that does not comprise the one or more stabilization domains.

It relates to siRNA, e.g., double stranded ribonucleic acid (dsRNA), that interfere with target gene expression or inhibit its expression. It also relates to a conjugate or a pharmaceutical composition containing the siRNA. And the use of the siRNA, the conjugate and the pharmaceutical composition thereof in preparing a drug used for treating and / or preventing the disease or disorder.

The disclosure relates to cancer ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.

The disclosure relates to double-stranded ribonucleic acid (dsRNA) targeting an INHBE gene, and methods of using the dsRNA to inhibit expression of INHBE.

The invention relates to adaptors for sequencing nucleic acids. The adaptors may be used to generate single stranded constructs of nucleic acid for sequencing purposes. Such constructs may contain both strands from a double stranded deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) template. The invention also relates to the constructs generated using the adaptors, methods of making the adaptors and constructs, as well as methods of sequencing double stranded nucleic acids.

The present disclosure relates in some aspects to methods, systems, and kits for analyzing a biological sample comprising generating a rolling circle amplification product (RCP) using a target ribonucleic acid (RNA) as a primer. In some aspects, RNase H and a nucleic acid oligonucleotide are used to generate a free 3′ end of the target RNA to prime RCA.

The invention discloses a novel application of emodin as an endonuclease inhibitor. The emodin inhibits replication and transmission of viruses by inhibiting the activity of NSP15 ribonuclease, and recovers host interferon reaction so as to enhance the antiviral effect. The application has the advantages that the action target of the emodin is defined, the effectiveness of the emodin in the aspect of preventing and treating coronavirus infection is further revealed, and the broad-spectrum antiviral potential of the emodin is embodied through the link of playing the antiviral effect by inhibiting the virus replication link; the researches provide candidate drugs and scientific basis for research and development of novel broad-spectrum anti-coronavirus drugs, and promote clinical application of the anti-virus traditional Chinese medicines.

The invention provides a ribonucleic acid (RNA) structure searching method and device and electronic equipment, and relates to the technical field of artificial intelligence, biological calculation and the like. According to the specific implementation scheme, the method comprises the steps that a first discretization sequence of a first RNA structure to be searched is obtained and serves as a query sequence; based on the query sequence, performing index search in a pre-constructed RNA structure database, and determining a hit index sequence; and according to the query sequence and the hit index sequence, carrying out structure search in the RNA structure database, and determining at least one target RNA structure corresponding to the first RNA structure. Therefore, the target RNA structure is determined by performing discretization processing on the RNA structure and performing structure search in the pre-constructed RNA structure database, so that the complexity of obtaining the RNA structure is reduced, and the efficiency and accuracy of obtaining the RNA structure are improved.

The invention provides a correlation prediction model training method, a correlation prediction method and a correlation prediction system, and the method comprises the steps: obtaining a plurality of training samples which are obtained through the construction of first sample multi-source features and second sample multi-source features with correlation labels, the first sample multi-source feature is a multi-source feature corresponding to sample micro ribonucleic acid, and the second sample multi-source feature is a multi-source feature corresponding to a sample physiological state type; inputting the plurality of training samples into a preset model, and training the preset model based on vertex vector representation output by a fusion feature layer of the preset model to obtain a trained association prediction model; and the fusion feature layer is used for carrying out fusion processing on the global attention fusion feature representation and the local attention fusion feature representation to obtain vertex vector representation. According to the invention, the association prediction accuracy of miRNA and physiological status types is improved.

The invention provides a pseudovirus of a Nipah virus and application of the pseudovirus, and belongs to the technical field of genetic engineering. The invention provides a pseudovirus of a Nipah virus and application of the pseudovirus. The pseudovirus contains a nucleic acid fragment of a Nipah virus N gene of which the nucleotide sequence is shown as SEQ ID NO.1. The invention further provides a preparation method of the pseudovirus. The pseudovirus of the Nipah virus can be used as a ribonucleic acid standard substance of the pseudovirus of the Nipah virus, and is applied to the aspects of quantity transmission, calibration, instrument testing, evaluation and control of a testing method, quality verification, quality control, production process detection and the like of a laboratory related to Nipah virus detection. The pseudovirus of the Nipah virus, as the ribonucleic acid standard substance of the pseudovirus of the Nipah virus, has the following advantages of accurate fixed value, good uniformity, stable quantity value and traceability, and can promote the improvement of the detection capability and the technical level of a national Nipah detection laboratory.

96 New PCT-Patent Application based on EP 24 186 635.9 Insempra GmbH Vossius Ref.: AG4141 PCT S3 Abstract The present invention relates to a linear double-stranded deoxyribonucleic acid (dsDNA) molecule comprising one or more Tus protein (Tus) binding site(s) at the 5'-terminus, one or more Lac repressor protein (LacI) binding site(s) at the 3'-terminus, and a segment comprising a DNA sequence of interest (DOI) between said Tus binding site(s) and said LacI binding site(s). The present invention further relates to a non-naturally or naturally occurring RNA molecule as encoded by or transcribable / transcribed from the linear dsDNA molecule of the invention, and to an expression DNA cassette comprising a promoter, an RBS, a GOI encoding a POI, and one or more LacI binding site(s), wherein said expression cassette does not comprise a terminator sequence between the 3´ end of said GOI and said one or more LacI binding site(s). The present invention also relates to a non-naturally or naturally occurring RNA molecule as encoded by or transcribable / transcribed from said expression cassette. The present invention further relates to method of protecting a linear deoxyribonucleic acid (DNA) molecule from exonuclease degradation by adding one or more Tus binding site(s) at the first terminus of the DNA molecule and adding one or more LacI binding site(s) at the other terminus of the DNA molecule. The present invention further relates to a method of synthesizing a protein of interest (POI) in a cell- free protein synthesis (CFPS) reaction mixture by using the (ds)DNA and / or RNA molecules of the invention, and also to a cell-free biological system or CFPS reaction mixture comprising the (ds)DNA, expression cassette and / or RNA molecules of the invention.

The invention provides double-stranded ribonucleic acid for reducing blood coagulation factor XI expression and a modifier and application of the double-stranded ribonucleic acid. Cell experiment results show that the oligonucleotide duplex can significantly inhibit the expression of the FXI gene, and can be used for developing anticoagulant drugs.

The invention discloses an extraction method and application of high-molecular-weight turbellarian worm genome DNA, and belongs to the field of turbellarian worm genome extraction.The turbellarian worm genome DNA extraction is achieved by improving a lysate formula and removing ethylenediaminetetraacetic acid and increasing Mg < 2 + > on the basis of a conventional reagent in a classic Tris-HCl-phenol-chloroform method to inhibit activity of deoxyribonuclease II in a turbellarian worm body to inhibit degradation of genome DNA, and the high-molecular-weight turbellarian worm genome DNA is obtained. Meanwhile, ribonuclease A is added, RNA in cells can be degraded in the tissue cell digestion process, so that the step of two times of purification is omitted, the loss of DNA yield is reduced, experimental steps are simplified, especially the step of DNA purification is reduced, the problem of degradation in the extraction process of the turbellarian turbellarian worm genome DNA is solved, and the genome DNA yield (gt; 10 micrograms per turbellarian worm), and the turbellarian worm genome ultra-long sequencing or PacBio high-fidelity sequencing requirements are met.

The present disclosure is directed to a system 100 and a method 300 for predicting binding affinity of small molecules to Ribo-Nucleic Acid (RNA) targets The method comprises of receiving an input from a user, comprising a sequence of an RNA target, information related to a small molecule and a sub-type of the RNA target. The method further comprises of predicting a binding affinity of the small molecule to the RNA target of the sub-type, using a prediction model. Generating the prediction model comprises of, obtaining a plurality of RNA sequence based features for a plurality of sub-types of a plurality of RNA targets, and a plurality of small molecule features for a plurality of small molecules. Generating the prediction model further comprises of identifying a plurality of non-correlated features from the plurality of RNA sequence based features and the plurality of small molecule features and generating a final feature combination from the plurality of non- correlated features for each sub-type of the plurality of sub-types of the plurality of RNA targets based on a quasi-binding affinity of each of the plurality of small molecules with each sub-type of the plurality of sub-types of the plurality of RNA targets. The final feature combination is used to generate the prediction model.

Disclosed herein is a modified ribonucleotide comprising a nucleoside comprising 2′-O-acetylated ribose, and polyribonucleotides comprising the same. Also provided herein are compositions comprising a polyribonucleotide of the present disclosure and methods of making and using the same.

The invention relates to the technical field of medicines, and discloses a stress particle targeted degradation agent as well as a preparation method and application thereof. The compound provided by the invention comprises a ternary complex composed of a stress particle protein, a linking group and an E3 ubiquitin ligase ligand or a ternary complex composed of a stress particle protein, a linking group and a ribonuclease L ligand, the compounds connected with different ligands have good targeting and degradation effects on the stress particles, can be used as a stress particle targeting degradation agent to be applied to preparation of anti-tumor drugs and anti-neurodegenerative disease drugs, and have good application prospects in treatment of stress particle induced tumor drug resistance and neurodegenerative diseases.

A method of reducing the level of a transcription product in a cell comprising contacting with the cell a composition comprising a double-stranded nucleic acid complex comprising a first nucleic acid strand annealed to a second nucleic acid strand, wherein: (i) the first nucleic acid strand hybridizes to the transcription product and comprises (a) a region consisting of at least 4 consecutive nucleotides that are recognized by RNase H when the strand is hybridized to the transcription product, (b) one or more nucleotide analogs located on 5′ terminal side of the region, (c) one or more nucleotide analogs located on 3′ terminal side of the region and (d) a total number of nucleotides and nucleotide analogs ranging from 8 to 35 nucleotides and (ii) the second nucleic acid strand comprises (a) nucleotides and optionally nucleotide analogs and (b) at least 4 consecutive RNA nucleotides.

This application relates to a deoxyribonucleic acid and pseudovirus preservation solution, its preparation method and application. The deoxyribonucleic acid and pseudovirus preservation solution includes: a buffer solution with a final concentration of 5 mM to 50 mM, a surfactant with a volume percentage of 0.05% to 1.0%, trehalose with a final concentration of 50 mM to 500 mM, a metal ion chelator with a final concentration of 0.5 mM to 5 mM, betaine with a final concentration of 100 mM to 1000 mM, and mannitol with a mass percentage of 1% to 10%. Each specific component in the above-mentioned deoxyribonucleic acid and pseudovirus preservation solution cooperates with each other at a specific concentration, which has the effect of stabilizing the state and structure of nucleic acids. It can achieve the preservation of nucleic acids and pseudoviruses without ultra-low temperature, and can stably preserve nucleic acids and pseudoviruses for up to 12 months at 30°C without affecting subsequent detection tests.

The invention relates to pharmaceutical compositions comprising an iRNA agent, e.g., double stranded ribonucleic acid (dsRNA) agent and methods of using such compositions to treat a bleeding event in a subject having a hemophilia (e.g., with or without inhibitors).

The present disclosure provides siRNAs, modifiers, conjugates and uses thereof for targeted regulation of Factor 11 of coagulation (FXI) gene expression. A series of siRNAs are designed based on an FXI messenger ribonucleic acid (mRNA) sequence, alternate modification is carried out, and modification is carried out by utilizing a group of specific modification templates. Cellular and animal experiment results show that some alternately modified and specific template modified oligonucleotide sequences can significantly inhibit the expression of the FXI gene, and can be used for developing anticoagulant drugs.

The present invention relates to iRNA, such as double-stranded ribonucleic acid (dsRNA), compositions targeting complement component C5 gene and methods of using such iRNA (e.g., dsRNA), compositions to inhibit the expression of C5 and treat subjects suffering from a complement component C5-associated disease (e.g., paroxysmal nocturnal hemoglobinuria).

The present application relates to double-stranded RNA (dsRNAi) agents and compositions targeting the APP gene, as well as methods of using the dsRNAi agents and compositions to inhibit the expression of the APP gene and methods of treating individuals suffering from APP-related diseases or disorders, such as cerebral amyloid angiopathy (CAA) and early-onset familial Alzheimer's disease (EOFAD or eFAD).

The invention provides a respiratory system fungal infection detection system, a kit and a preparation method thereof, and belongs to the technical field of biological detection. The primer probe composition used by the respiratory system fungal infection detection system comprises upstream and downstream primers and a fluorescent probe sequence designed aiming at paracoccus braziliensis, upstream and downstream primers and a fluorescent probe sequence designed aiming at histoplasma capsulatus, and upstream and downstream primers and a fluorescent probe sequence designed aiming at troptosporidium. The kit comprises upstream and downstream primers and fluorescent probe sequences designed for budgettes dermatitis, upstream and downstream primers and fluorescent probe sequences designed for Sirpolyspora sessilifolia, upstream and downstream primers and fluorescent probe sequences designed for talaromyces marneffei, upstream and downstream primers and fluorescent probe sequences designed for internal reference designed for ribonuclease P, upstream and downstream primers and fluorescent probe sequences designed for ribonuclease P, upstream and downstream primers and fluorescent probe sequences designed for ribonuclease P, and upstream and downstream primers and fluorescent probe sequences designed for ribonuclease P, the kit can be used for effectively detecting the fungi of the respiratory system, and ensures high accuracy, specificity and sensitivity.